https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-appoints-jonathan-m--poole-to-its-board-of-directors
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole...
board of directorsacadia pharmaceuticalsjonathanpoole
https://salesandmarketingnetwork.com/news_release_bs.html?pipe=0000ac177000191&ID=2023943&key=Pimavanserin
News for Medical Sales Reps: ACADIA Pharmaceuticals Initiates Second Phase III Trial with...
phase iii trialfor medicalsales repsacadia pharmaceuticalsnews
https://iowahealthcare.org/vendor-finder/acadia-pharmaceuticals/?print=1
ACADIA Pharmaceuticals - Iowa Health Care Association
Apr 7, 2026 - Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital...
acadia pharmaceuticalshealth careiowaassociation
https://www.biospace.com/press-releases/acadia-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2024-financial-results-on-february-26-2025
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February...
acadia pharmaceuticalsfull yearfinancial resultsannouncefourth
https://app.ortex.com/s/Nasdaq/ACAD/currency-exposure
ACADIA Pharmaceuticals Inc., Nasdaq:ACAD | Currency Exposure - ORTEX
Currency Exposure and correlations for ACADIA Pharmaceuticals Inc., Nasdaq:ACAD
acadia pharmaceuticalsincnasdaqcurrencyexposure
https://biopharmabytes.com/expert-analysis-on-acadia-pharmaceuticals/
Expert Analysis on ACADIA Pharmaceuticals - Biopharma Bytes
Jun 8, 2025 - As a frontrunner in the realm of central nervous system disorders and rare diseases, Acadia Pharmaceuticals Inc. has been making waves in the biotech industry...
expert analysisacadia pharmaceuticalsbiopharmabytes
https://koalagains.com/stocks/NASDAQ/ACAD
ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis & Key Metrics (2026)
Analysis of ACADIA Pharmaceuticals (ACAD) reveals a mixed outlook. While financially stable, its reliance on one drug and a risky pipeline create uncertainty.
acadia pharmaceuticalsstock analysiskey metricsinc
https://news.vumc.org/old-tag/acadia-pharmaceuticals/
Acadia Pharmaceuticals Archives - Vanderbilt Health News
vanderbilt health newsacadia pharmaceuticalsarchives
https://www.home.saxo/cs-cz/markets/stocks/acad-xnas
ACADIA Pharmaceuticals Inc. akcie | Saxo Bank
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare...
acadia pharmaceuticalssaxo bankincakcie
https://crueltyfreeinvesting.org/companies/acadia-pharmaceuticals-inc/
ACADIA Pharmaceuticals Inc. - Cruelty Free Investing
Oct 17, 2025 - Acadia Pharmaceutical is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in...
acadia pharmaceuticalscruelty freeincinvesting
https://stocks.proximilar.com/ACAD/main
ACADIA PHARMACEUTICALS INC Stock Forecasts | ACAD EPS & Price Predictions
ACADIA PHARMACEUTICALS INC Stock Forecasts | ACAD Earnings, Revenue and Price Estimates
acadia pharmaceuticalsstock forecastsprice predictionsinceps
https://stocksscreener.com/stocks/ACAD
ACADIA Pharmaceuticals Inc. | ACAD Overview | Stocks Screener
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in...
acadia pharmaceuticalsstocks screenerincoverview
https://www.prnewswire.com/news-releases/investors-get-options-trading-reports-for-acadia-pharmaceuticals-advanced-micro-devices-allegheny-technologies-host-hotels-and-resorts-and-microsoft-include-trade-ideas-that-offer-returns-of-21-or-more-300382474.html
Investors: Get options trading reports for ACADIA Pharmaceuticals, Advanced Micro Devices,...
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, AMD, ATI, HST, and MSFT. To see the high-return covered-call trades uncovered...
advanced micro devicesget optionstrading reportsfor acadiainvestors
https://www.fibogroup.com/analytics-and-training/shares/ACAD/
ACAD: Charts, Quotes | Stock Prices Acadia Pharmaceuticals Inc in real time | Buy Shares | FIBO...
Discover the world of stock trading online with FIBO Group! We provide the latest toolkit for best buy and sell ACAD stocks with accurate charts for tracking...
stock pricesacadia pharmaceuticalsreal timechartsquotes
https://www.wallstreetzen.com/stocks/us/nasdaq/acad/revenue
(ACAD) Acadia Pharmaceuticals Revenue: 2001-2026 Annual Revenue | WallStreetZen
acadia pharmaceuticalsrevenueannual
https://wiseek.ai/ticker/acad/acadia-pharmaceuticals-reports-strong-q1-revenue-growth-reaffirms-2026-guidance-000119312526209253/
Acadia Pharmaceuticals Reports Strong Q1 Revenue Growth, Reaffirms 2026 Guidance
May 6, 2026 - Acadia Pharmaceuticals announced its first quarter 2026 financial results, reporting significant revenue growth for its key products DAYBUE and NUPLAZID.
acadia pharmaceuticalsrevenue growthreportsstrongguidance
https://www.cabotwealth.com/premium/wall-streets-best-digest/alert/acadia-pharmaceuticals-acad
Acadia Pharmaceuticals (ACAD) - Cabot Wealth Network
acadia pharmaceuticalscabotwealthnetwork
https://www.motilaloswal.com/us-stocks/acad
ACADIA Pharmaceuticals Inc. Share Price Today - ACAD Stock Price Quote
acadia pharmaceuticalsshare pricestock quoteinctoday
https://www.resumemate.io/jobs/ai-jobs-in-san-diego/7e7a1e_acadiapharmaceuticals_8486109002
Senior Director Commercial Advanced Analytics & Data Strategy at Acadia Pharmaceuticals Inc. |...
senior directoradvanced analyticsdata strategyacadia pharmaceuticalscommercial
https://pharmadevicenews.com/acadia-pharmaceuticals-broadens-rett-syndrome-treatment-flexibility-with-daybue-stix-rollout-in-the-united-states/
Acadia Pharmaceuticals broadens Rett syndrome treatment flexibility with DAYBUE STIX rollout in the...
Apr 8, 2026 - Acadia Pharmaceuticals has launched DAYBUE STIX for Rett syndrome in the U.S. Read what this means for adoption, tolerability, and market strategy.
acadia pharmaceuticalsrett syndrometreatmentflexibilitystix
https://www.schca.org/associate-members/acadia-pharmaceuticals/?print=1
Acadia Pharmaceuticals - South Carolina Health Care Association
Apr 21, 2026 - Pharmaceuticals/Parkinsons
acadia pharmaceuticalssouth carolinahealth careassociation
https://marketxls.com/stocks/ACAD
ACAD Stock - ACADIA Pharmaceuticals Inc. Price & Analysis | MarketXLS
ACADIA Pharmaceuticals Inc. (ACAD) stock analysis. Current price: $$20.95, Market cap: $3.55B. View real-time data, financials, charts, dividends, and...
acadia pharmaceuticalsprice analysisstockinc
https://remoteleaf.com/company/acadia-pharmaceuticals/sr-family-support-educator-mid-atlantic-united-states/
(Sr.) Family Support Educator, Mid-Atlantic at Acadia Pharmaceuticals - Remote
Apply for Remote (Sr.) Family Support Educator, Mid-Atlantic at Acadia Pharmaceuticals. $124,000-$155,000/year. Find hand-screened remote jobs on RemoteLeaf....
family supportmid atlanticacadia pharmaceuticalssreducator
https://www.panabee.com/news/acadia-pharmaceuticals-earnings-q2-2025
Acadia Pharmaceuticals Earnings Q2 2025 | Acadia Pharmaceuticals News & Analysis
Acadia Pharmaceuticals reported a 9% rise in total revenues, driven by robust sales of NUPLAZID and DAYBUE, and fortified its intellectual property. However,...
acadia pharmaceuticalsnews analysisearnings
https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=ACAD
ACAD Stock Charts, Analysis, Trend, Acadia Pharmaceuticals Inc
ACAD, Acadia Pharmaceuticals Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis...
stock chartsacadia pharmaceuticalsanalysistrendinc